Biotech Values

[Rocky3]

Page 43 of GILD slide deck shows GILD at 61% of US HCV market - up 19% from Jan 19. Also interesting is that patient starts have stayed very high (JMO). Since US HCV revenue flat YOY when starts are up >30%, it must be from lower pricing (generic).